Financial·Reported by 4 outside sources·
ORIC Pharmaceuticals launched a Phase 3 clinical trial for its lead prostate cancer drug rinzimetostat.
- Who
- ORIC Pharmaceuticals, Inc.
- Where
- global
- When
- Why
- to convert years of early work into late-stage bets for its prostate cancer drug
via marketaux